ArticleJournal of medical biochemistry2026
Multifaceted roles of superoxide dismutases (SODs) in cellular homeostasis and cancer progression: Redox regulation and therapeutic implications.
Article in Journal of medical biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Decoupling metabolic defense: Mutational and recombinational chaos in Sod1-deficient cells.PLoS genetics · 2026Article
- Redox Regulation in Glioblastoma: Mechanisms, Biomarkers, and Therapeutic Implications.International journal of molecular sciences · 2026Review
- Size-Dependent Differences in the Effects of Low-Dose Selenium Nanoparticles on Chronic Thioacetamide Toxicosis Accompanying HCC Progression in Mice.Biological trace element research · 2026Article
- Redox Imbalance and Antioxidant Adaptation in Acute Ischemic Stroke: Temporal Changes in Enzymatic and Non-Enzymatic Markers.Molecules (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Superoxide dismutases (SODs) are critical metalloenzymes that regulate cellular redox homeostasis by catalysing the dismutation of superoxide radicals into hydrogen peroxide and oxygen, thereby mitigating oxidative stress. Comprising three isoforms - SOD1 (Cu/Zn-SOD), SOD2 (Mn-SOD), and SOD3 (ecSOD) - these enzymes are localised in distinct cellular compartments, including the cytosol, mitochondria, and extracellular matrix, respectively. SODs play pivotal roles in cellular signalling, metabolism, and protection against reactive oxygen species (ROS)-mediated damage. Dysregulation of SOD expression and activity is implicated in various pathological conditions, particularly cancer, where they influence tumour initiation, progression, metastasis, and therapy resistance. Elevated SOD1 and SOD2 levels often promote oncogenic signalling and tumour survival, whereas SOD3 exhibits context-dependent roles, balancing tumour suppression and progression. Additionally, SOD mimetics, notably manganese-based compounds such as Mn-porphyrins and Mn-salens, have emerged as promising therapeutic agents that selectively modulate oxidative stress in cancer cells, thereby enhancing the efficacy of chemotherapy and radiotherapy while protecting normal tissues. This review explores the multifaceted roles of SODs in cellular homeostasis, their involvement in cancer pathogenesis, and the therapeutic potential of SOD mimetics in redox-based cancer strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.